drugset / Trial / NCT05648994
TCR-T Cells for the Treatment NY-ESO-1-positive Advanced Solid Tumors
NaSequentialOpen-labelTreatment
Summary
New York Esophageal Squamous Cell Carcinoma 1 (NY-ESO-1) is a Cancer-Testis Antigen (CTA) which is expressed in various tumors. After selected the high affinity TCR gene to NY-ESO-1, the researchers insert genes into the cell that expressing a kind of protein that targeting NY-ESO-1. Then the engineered cells are re-infused in the patients with tumors for curing the tumor patient or prolonging life.
Timeline
- Start
- 2022-12
- Primary completion
- 2024-02
- Completion
- 2026-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TCR-T cells | Cell therapy | — | — |
| Background | Cyclophosphamide | Other / unclassified | — | — |
| Background | Fludarabine | Small molecule | — | — |
| Background | Paclitaxel | Small molecule | — | — |
| Background | aldesleukin | Protein / enzyme biologic | — | — |